Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway

Fig. 6

Eugenol sensitizes ovarian cancer cells to cisplatin in vivo. a Experimental design: Mice (n = 10/group) harboring tumors were treated with DMSO (control), cisplatin, eugenol and both drugs for 3 weeks. Xenografts were harvested from half the mice at the completion of treatment (n = 5/group), and the remaining xenografts (n = 5/group) were harvested 1 month later. b and c [Top panels] During the treatment period tumor volumes were measured [Bottom panels] weighted tumor masses at harvest. ‘p’ values from One-way ANOVA on graphs and Eug vs Eug + Cis = *p 0.05; ***p 0.001 and Cis vs Eug + Cis = ****p 0.0001, respectively by unpaired two-sided t-test. d H&E as well as immunostaining using antibodies against the indicated proteins. The graph bar represents quantification of the Ki-67 immunofluorescence. (n = 3, mean +/− SD; Students t-Test;*p 0.05, ** p 0.01, *** p 0.001). e and f. Tumor masses at harvest. ‘p’ values from Eug vs Eug + Cis = **p 0.01; and Cis vs Eug + Cis = **p 0.01, respectively by unpaired two-sided t-test. g and h. Tumor-free survivals were determined following 30-days post cessation of treatment (Log-rank test p values: 0.003 and 0.18)

Back to article page